Health Care·Pharmaceuticals·$153.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.98 | N/A | +0.20% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.98 | N/A | +0.20% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting their commitment to innovation. However, they did not provide specific revenue figures or guidance.
We are pleased with our EPS performance this quarter.
Our focus remains on delivering innovative solutions to our customers.
Pfizer's earnings report showed a positive surprise in EPS, which contributed to a 3.21% increase in stock price. The lack of revenue data and guidance leaves some uncertainty, but the EPS beat suggests strong performance in key areas. Investors may view this as a sign of resilience amid ongoing market challenges.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SOUTHERN COPPER CORP
Jul 26, 2021